Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis, a valvular heart condition that can be deadly ...

Aortic stenosis is a condition where the aortic valve narrows, obstructing blood flow from the heart to the aorta. As a ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...

1 Aortic stenosis is generally well tolerated for a ... However, once symptoms (typically, of heart failure) develop, the prognosis is poor.

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Researchers have shed new light on how a type of heart valve disease -- aortic valve stenosis -- progresses differently in males and females.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...